SCHEMBL7486202

SCHEMBL7486202

O=C(Nc1ccc([N+](=O)[O-])cc1O)Nc1ccccc1OCc1ccccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR1 P25024 3/20 0.57
CXCR2 P25025 3/20 0.57
PPIA P62937 1/20 0.56
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
TDP1 Q9NUW8 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
MAPT P10636 3/20 0.54
KCNMA1 Q12791 2/20 0.52
CYP19A1 P11511 1/20 0.49
TP53 P04637 1/20 0.47
HTT P42858 1/20 0.47
PLA2G1B P04054 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
GAA P10253 2/20 0.46
CTSV O60911 1/20 0.45
CTSL P07711 1/20 0.45
ALDH1A1 P00352 1/20 0.45
AKR1C4 P17516 1/20 0.43
AKR1C3 P42330 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7549656 0.90 KMT2A (0.57) CXCR1CXCR2PPIAMEN1KMT2A
SCHEMBL7549892 0.84 KMT2A (0.57) CXCR1CXCR2PPIAMEN1KMT2A
SCHEMBL7487951 0.82 CXCR1 (0.63) CXCR1CXCR2PPIAMEN1KMT2A
SCHEMBL5594899 0.82 KMT2A (0.63) CXCR1CXCR2PPIAMEN1KMT2A
SCHEMBL7549869 0.81 MEN1 (0.62) CXCR1CXCR2PPIAMEN1KMT2A
SCHEMBL7489143 0.81 PPIA (0.62) CXCR1CXCR2PPIAMEN1KMT2A
SCHEMBL3708973 0.79 CXCR1 (0.67) CXCR1CXCR2PPIAMEN1KMT2A
SCHEMBL7484203 0.78 PPIA (0.59) CXCR1CXCR2PPIAMEN1KMT2A
SCHEMBL6820169 0.78 KMT2A (0.68) CXCR1CXCR2MEN1KMT2ATDP1
SCHEMBL3710415 0.78 KMT2A (0.68) CXCR1CXCR2MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0896531-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-30 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
EP-0896531-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-17 EP disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN CXCR1 21/4885CXCR2 15/4885PPIA 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.